




AMENDMENTS TO THE CLAIMS

Claims 1-30 (cancelled)

Claim 31 (currently amended): A method for ~~affecting~~ promoting the survival or function of dopaminergic neurons comprising administering a polynucleotide consisting of a polynucleotide sequence encoding a truncated glial cell line-derived neurotrophic factor (GDNF) protein product consisting of an amino acid sequence



wherein

[Cys⁴¹-Cys¹³³] consists of Cys⁴¹ through Cys¹³³ of SEQ ID NO 2;

Y represents the carboxy terminal group of Cys¹³³, a carboxy-terminus amino acid residue of Ile¹³⁴, or a substituted amino acid residue, and

X represents a methionylated or nonmethionylated amine group of Cys⁴¹ or amino-terminus amino acid residue(s) selected from the group:

B1

	G	
	RG	
	NRG	
	KNRG	(SEQ ID NO:3)
	GKNRG	(SEQ ID NO:4)
	RGKNRG	(SEQ ID NO:5)
	QRGKNRG	(SEQ ID NO:6)
	GQRGKNRG	(SEQ ID NO:7)
	RGQRGKNRG	(SEQ ID NO:8)
	RRGQRGKNRG	(SEQ ID NO:9)
G	RRGQRGKNRG	(SEQ ID NO:10)
KG	RRGQRGKNRG	(SEQ ID NO:11)
GKG	RRGQRGKNRG	(SEQ ID NO:12)
RGKG	RRGQRGKNRG	(SEQ ID NO:13)
SRGKG	RRGQRGKNRG	(SEQ ID NO:14)
NSRGKG	RRGQRGKNRG	(SEQ ID NO:15)
ENSRGKG	RRGQRGKNRG	(SEQ ID NO:16)
PENSRGKG	RRGQRGKNRG	(SEQ ID NO:17)
<u>SPENSRGKG</u>	<u>RRGQRGKNRG</u>	<u>(SEQ ID NO:51)</u>
NPENSRGKG	RRGQRGKNRG	(SEQ ID NO:18)
ANPENSRGKG	RRGQRGKNRG	(SEQ ID NO:19)
A	ANPENSRGKG	(SEQ ID NO:20)
AA	ANPENSRGKG	(SEQ ID NO:21)

RECEIVED

AUG 04 2003

TECH CENTER 1600/2900

AAA	ANPENS	RGKG	RRGQ	RGKN	RG	(SEQ ID NO:22)
QAAA	ANPENS	RGKG	RRGQ	RGKN	RG	(SEQ ID NO:23)
RQAAA	ANPENS	RGKG	RRGQ	RGKN	RG	(SEQ ID NO:24)
NRQAAA	ANPENS	RGKG	RRGQ	RGKN	RG	(SEQ ID NO:25)
RNRQAAA	ANPENS	RGKG	RRGQ	RGKN	RG	(SEQ ID NO:26)
ERNRQAAA	ANPENS	RGKG	RRGQ	RGKN	RG	(SEQ ID NO:27)
RERNRQAAA	ANPENS	RGKG	RRGQ	RGKN	RG	(SEQ ID NO:28)
RRERNRQAAA	ANPENS	RGKG	RRGQ	RGKN	RG	(SEQ ID NO:29)
P	RRERNRQAAA	ANPENS	RGKG	RRGQ	RGKN	RG (SEQ ID NO:30)
LP	RRERNRQAAA	ANPENS	RGKG	RRGQ	RGKN	RG (SEQ ID NO:31)
VLP	RRERNRQAAA	ANPENS	RGKG	RRGQ	RGKN	RG (SEQ ID NO:32)
AVLP	RRERNRQAAA	ANPENS	RGKG	RRGQ	RGKN	RG (SEQ ID NO:33)
MAVLP	RRERNRQAAA	ANPENS	RGKG	RRGQ	RGKN	RG (SEQ ID NO:34)
QMAVLP	RRERNRQAAA	ANPENS	RGKG	RRGQ	RGKN	RG (SEQ ID NO:35)
KQMAVLP	RRERNRQAAA	ANPENS	RGKG	RRGQ	RGKN	RG (SEQ ID NO:36)
DKQMAVLP	RRERNRQAAA	ANPENS	RGKG	RRGQ	RGKN	RG (SEQ ID NO:37) and
PDKQMAVLP	RRERNRQAAA	ANPENS	RGKG	RRGQ	RGKN	RG (SEQ ID NO:38)

B1 cont
or a substitution or deletion variant of X, wherein said variant is in excess of 70% identical to an amino acid sequence of X as set forth above when four gaps in a length of 100 amino acids may be introduced to assist in that alignment, to provide *in vivo* production of said truncated GDNF protein.

Claims 32-44 (cancelled)

Claim 45 (currently amended): A method according to Claim 31 or 32, wherein X is selected from the group consisting of SEQ ID NO: 3, 7, 8, 14, 17, and 18 and 24.

Claim 46 (previously presented): A method according to Claim 31 or 32, wherein X is G, RG or NRG.

Claim 47 (previously presented): A method according to Claim 31 or 32, wherein said GDNF protein product has the amino acid sequence of SEQ ID NO:42.

next pg.
B
Claim 48 (previously presented): A method according to Claim 31 or 32, wherein said GDNF protein product has the amino acid sequence of SEQ ID NO:44.

Claim 49 (previously presented): A method according to Claim 31 or 32, wherein said GDNF protein product has the amino acid sequence of SEQ ID NO:46.